108 related articles for article (PubMed ID: 36054307)
41. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
42. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.
Ma Y; Wei Z; Bast RC; Wang Z; Li Y; Gao M; Liu Y; Wang X; Guo C; Zhang L; Wang X
Lab Invest; 2016 Jan; 96(1):37-48. PubMed ID: 26568293
[TBL] [Abstract][Full Text] [Related]
43. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
44. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
[TBL] [Abstract][Full Text] [Related]
45. NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.
Xu W; Gu J; Ren Q; Shi Y; Xia Q; Wang J; Wang S; Wang Y; Wang J
Tumour Biol; 2016 Apr; 37(4):4493-500. PubMed ID: 26501422
[TBL] [Abstract][Full Text] [Related]
46. Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2.
Wang S; Wang Z; Li J; Qin J; Song J; Li Y; Zhao L; Zhang X; Guo H; Shao C; Kong B; Liu Z
Cell Death Dis; 2021 Mar; 12(4):294. PubMed ID: 33731694
[TBL] [Abstract][Full Text] [Related]
47. miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1.
Guo J; Xia B; Meng F; Lou G
Biochem Biophys Res Commun; 2013 Nov; 441(2):357-63. PubMed ID: 24144591
[TBL] [Abstract][Full Text] [Related]
48. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
49. Human ovarian cancer of the surface epithelium.
Berchuck A; Carney M
Biochem Pharmacol; 1997 Sep; 54(5):541-4. PubMed ID: 9337069
[TBL] [Abstract][Full Text] [Related]
50. MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer.
Zhao S; Zhang X; Shi Y; Cheng L; Song T; Wu B; Li J; Yang H
J Exp Clin Cancer Res; 2020 Dec; 39(1):286. PubMed ID: 33317572
[TBL] [Abstract][Full Text] [Related]
51. TRIM37 promotes the aggressiveness of ovarian cancer cells and increases c-Myc expression by binding to HUWE1.
Li D; Zhang Z
Arch Biochem Biophys; 2022 Oct; 728():109372. PubMed ID: 35921902
[TBL] [Abstract][Full Text] [Related]
52. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
53. Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.
Chen X; Zhang H; Aravindakshan JP; Gotlieb WH; Sairam MR
Oncogene; 2011 Jun; 30(25):2874-87. PubMed ID: 21339736
[TBL] [Abstract][Full Text] [Related]
54. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
55. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice.
Xu X; Ayub B; Liu Z; Serna VA; Qiang W; Liu Y; Hernando E; Zabludoff S; Kurita T; Kong B; Wei JJ
Mol Cancer Ther; 2014 Jul; 13(7):1729-39. PubMed ID: 24825857
[TBL] [Abstract][Full Text] [Related]
56. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
[TBL] [Abstract][Full Text] [Related]
57. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
[TBL] [Abstract][Full Text] [Related]
58. Mutant p53 expression in fallopian tube epithelium drives cell migration.
Quartuccio SM; Karthikeyan S; Eddie SL; Lantvit DD; Ó hAinmhire E; Modi DA; Wei JJ; Burdette JE
Int J Cancer; 2015 Oct; 137(7):1528-38. PubMed ID: 25810107
[TBL] [Abstract][Full Text] [Related]
59. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
[TBL] [Abstract][Full Text] [Related]
60. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DD
PLoS One; 2011 Apr; 6(4):e18064. PubMed ID: 21533284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
